510(k) Submissions Recent Experience and Perspectives Terry Sullivan Vice President, Regulatory Affairs.

Slides:



Advertisements
Similar presentations
Interpreting & Applying the Standards October 4, 2006 Dr. Luis J. Pedraja, Vice President Middle States Commission on Higher Education.
Advertisements

A Review of Codevelopment and Companion Dx Policy Elizabeth Mansfield, PhD Director, Personalized Medicine Staff OIR/CDRH/FDA NCCS Cancer Policy Roundtable.
Replacement Reagent Policy Update
"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.
November 19, 2013 Preparing a Successful RFP to get Desired Results.
Complying with FSMA: What a cashew exporter to the U.S. needs to do.
CBER 510(k) Challenges and Strategies Susan Finneran Director of Clinical and Regulatory Affairs.
510k Submission Overview Myraqa, Inc. August 22, 2012.
Recognition of Prior Learning (RPL) & Credit Transfers.
Accredited Third Party Certification and Food Safety Management Systems Jill Hollingsworth, DVM Group Vice President Food Marketing Institute.
CADTH Therapeutic Reviews
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
1Product certification CASCO Comms/ International Organization for Standardization.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
What it is and what it is used for?.  It is a type of writing by an author who is trying to get something. As a result, it is an extremely persuasive.
Regulatory Overview.
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
Slide 1 of 19 Rob Packard, President
Justina A. Molzon, MS Pharm, JD
Literature Review and Parts of Proposal
Legal Issues Impacting Clinical Trials Medical Device Clinical Trials Update June 19, 2009.
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
This presentation, including any supporting materials, is owned by Gartner, Inc. and/or its affiliates and is for the sole use of the intended Gartner.
Slide 1 of 22 Rob Packard, President 510(k) Project Management.
CHANGES Fall 2012 The E-Rate Program. New and Recent Changes New – FY2013 Eligible Services List – Technology Plan requirement – Use of manufacturer’s.
Sustaining Community-Based Programs and Supporting Families: The Virginia Tech Interactive Training On Sustainability Training Developed by: Lydia I. Marek.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
OIVD Workshop Premarket Notification (510(k)) April 22, 2003 Parklawn Building Rockville, MD Presented by Marjorie Shulman Premarket Notification Staff.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
510(k) Process: Best Practices in Changing Times… MassMEDIC Massachusetts Medical Society, Waltham, MA April 1, :00 AM - 10:30 AM.
1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Biosimilars Where Are We Now? Where Are We Going? Sheldon Bradshaw January 24, 2008.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
Record Authenticity as a Measure of Trust: A View Across Records Professions, Sectors, and Legal Systems Corinne Rogers University of British Columbia.
IAEA International Atomic Energy Agency Methodology and Responsibilities for Periodic Safety Review for Research Reactors William Kennedy Research Reactor.
Parts of a Business Plan There are 16 essential parts to a business plan It can vary but you want it more specific as opposed to less specific Part one.
Webinar FSSC audit report 7th september 2015
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
The 510(k) Program Roy Baby, Investigator US Food & Drug Administration 4040 N Central Expressway, Dallas, TX 1.
Chapter Dental Public Health & Research Contemporary Practice for the Dental Hygienist Copyright ©2011 by Pearson Education, Inc. All rights reserved.
GU Advisory Panel Meeting Nocturnal Home Hemodialysis Draft Carolyn Y. Neuland, Ph.D. Chief, Gastroenterology and Renal Devices Branch Division of Reproductive,
IAEA International Atomic Energy Agency Development of the Basis Document for Periodic Safety Review for Research Reactors William Kennedy Research Reactor.
Training Session Product File Notes and Registration Reports, 23 October Registration Report Part Residues Frédéric Joris and Bruno Dujardin Federal.
AMERICAS | ASIA PACIFIC | EMEA Medical Devices: Concept to Commercialization How to avoid delays in getting your product cleared/approved by FDA Robert.
Radiology Advisory Panel Meeting Radiology Advisory Panel Meeting Computer-Assisted Detection (CADe) Devices Joyce M. Whang Deputy Division Director Radiological.
Moj Eram, PhD Senior Consultant ARC Experts, LLC 6 April, 2016
Regulatory Intelligence for the Emerging Markets Lisa Rysso-DeMaggio President, RAQUELIAN Consulting DIA Regulatory Intelligence Working Group, 10 Sep.
Director, Regulatory Affairs
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
FDA's Two New Draft Guidance on Software and Device
Communication: Safety Summary
Division of Cardiovascular Devices
IAEA E-learning Program
Premarket Notification 510(k) process
Irena Prat and Josée Hansen World Health Organization
CTD Content Management
Training Course on Integrated Management System for Regulatory Body
with Audrey Turley, B.S., RM (NRCM), CBA (ASQ)
the Public Procurement Audit Practical Guide
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Manuscripts and publishing
SPOT CHECKS 2016.
Presentation transcript:

510(k) Submissions Recent Experience and Perspectives Terry Sullivan Vice President, Regulatory Affairs

2 What I will cover today... Survey of audience Overview of 510(k) pathways –Traditional –Special –Abbreviated Perspective on some options available to manufacturers –STED –Third-Party review Perspective on Gyrus ACMI’s recent experience with submissions to FDA

3 Survey #’s of participants who are: –New to Regulatory Affairs profession? –Between 1 and 3 years experience? –Between 3 and 5 years experience? –More than 5 years experience?

4 Overview of 510(k) pathways All 510(k)s introduce new devices that are demonstrated to be substantially equivalent to another legally marketed device Elements of a substantial equivalence argument often include: –Same intended uses and same technological characteristics –Same intended uses and different technological characteristics but does not raise new questions of safety, and demonstrates that device is at least as safe and effective as predicate

5 Overview of 510(k) pathways Traditional 510(k)s typically introduce: –Significant changes in labeling –Significant performance changes –New clinical data needed for S&E or new S&E issues raised during design validation –Significant material changes FDA is under a 90-day time frame to review and make a determination

6 Overview of 510(k) pathways An example of a Traditional 510(k): –Predicate Device: Gyrus ACMI’s DUR-8 Flexible Ureteroscope, originally marketed under K012925

7 Overview of 510(k) pathways An example of a Traditional 510(k): –Proposed Device: Gyrus ACMI’s DUR-D Digital Flexible Ureteroscope, cleared under K060269

8 Overview of 510(k) pathways Special 510(k)s introduce changes to an existing device that do not: –Affect the intended uses of the device –Alter the fundamental scientific technology of the device Some changes that qualify for the Special pathway... Declaration of Conformity with Design Control requirements FDA is under a 30-day time frame to make a determination

9 Overview of 510(k) pathways An example of a Special 510(k): –Predicate Device: Gyrus ACMI’s ICN Digital Flexible CystoNephroscope, originally marketed under K042225

10 Overview of 510(k) pathways An example of a Special 510(k): –Proposed Device: Gyrus ACMI’s ICN Digital Flexible CystoNephroscope with VGA sensor, cleared under K090814

11 Overview of 510(k) pathways Abbreviated 510(k)s may be used for the same purposes as a Traditional 510(k), but rely on use of: –FDA Guidance Documents –Applicable Special Controls –FDA Recognized Standards Summary reports on use of Guidance or Special Controls Declarations of Conformity to Standards

12 Some manufacturer options STED format –Developed by GHTF, with intention to provide a harmonized format for use in multiple markets –Some limitations on application –In practice, we have found that STED in general isn’t sufficient for all our needs and have chosen to use a different approach

13 Some manufacturer options Third Party Review process – In theory, allows for faster reviews for a fee Has been discussed at some length internally –Some limitations on scope of this program –In practice, we have not chosen to utilize this option Budgets – greater cost to us Time savings isn’t significant enough for us

14 Perspectives on our experience A little background on Gyrus ACMI products... –Urology/Gynecology visualization and minimally invasive surgical devices –RF Energy devices for open and minimally invasive surgical procedures –ENT visualization, minimally invasive surgical procedures, otology implants In general, 98% of product portfolio falls within Class 1 or Class 2

15 Perspectives on our experience Gyrus ACMI’s experience with 510(k)s in general since mid-2005 –Most are Traditional 17 of 22 submitted –Balance are Special 5 of 22 submitted –By choice we do not use the Abbreviated pathway

16 Perspectives on our experience Planning for particular pathway –Begins with initial regulatory pathway assessments US: IDE/510(k)/PMA needed? Canada: License application needed? Europe: Tech File review needed? Latin America: registration dossiers needed? Pacific Rim: registration dossiers needed?

17 Perspectives on our experience As previously noted, almost all of our portfolio consists of Class 1 or Class 2 devices –Performance profile is pretty well known for these types of devices –Bench testing or animal testing is usually sufficient for our 510(k) submission –Pre-IDE approach has been used several times as part of our planning for more novel device designs or applications

18 Perspectives on our experience Since STED doesn’t really work for us, we format our submissions using a series of Sectional Templates built on: –“Guidance for Industry and FDA Staff: Format for Traditional and Abbreviated 510(k)s” Guidance/GuidanceDocuments/ucm htmhttp:// Guidance/GuidanceDocuments/ucm htm –“How To Prepare A Special 510(k)” Guidance/HowtoMarketYourDevice/PremarketSubmissio ns/PremarketNotification510k/ucm htm#contenthttp:// Guidance/HowtoMarketYourDevice/PremarketSubmissio ns/PremarketNotification510k/ucm htm#content

19 Perspectives on our experience How much information is too much detail? –Level of detail and description –Inclusion of test data/summaries

20 Perspectives on our experience Additional Information requests –Nature of requests varies –Often can be addressed through

21 Conclusion Lots of useful information about 510(k)s available from FDA on their Device Advice website – ionandGuidance/HowtoMarketYourDevice/Premar ketSubmissions/PremarketNotification510k/defaul t.htmhttp:// ionandGuidance/HowtoMarketYourDevice/Premar ketSubmissions/PremarketNotification510k/defaul t.htm Thank you for your time and attention!